Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent

Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B. Objec...

Full description

Bibliographic Details
Published in:Biomédica
Main Authors: María del Pilar Olaya, Nadezdha Esperanza Vergel, José Luis López, María Dolores Viña, Mario Francisco Guerrero
Format: Article in Journal/Newspaper
Language:English
Spanish
Published: Instituto Nacional de Salud 2019
Subjects:
R
Online Access:https://doi.org/10.7705/biomedica.4299
https://doaj.org/article/0bef9087aca8453f9c128e138c34846b
id ftdoajarticles:oai:doaj.org/article:0bef9087aca8453f9c128e138c34846b
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:0bef9087aca8453f9c128e138c34846b 2023-05-15T15:08:18+02:00 Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent María del Pilar Olaya Nadezdha Esperanza Vergel José Luis López María Dolores Viña Mario Francisco Guerrero 2019-09-01T00:00:00Z https://doi.org/10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b EN ES eng spa Instituto Nacional de Salud https://revistabiomedica.org/index.php/biomedica/article/view/4299 https://doaj.org/toc/0120-4157 0120-4157 doi:10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b Biomédica: revista del Instituto Nacional de Salud, Vol 39, Iss 3, Pp 491-501 (2019) Parkinson’s disease monoamine oxidase coumarins models animal reserpine levodopa haloperidol antioxidants Medicine R Arctic medicine. Tropical medicine RC955-962 article 2019 ftdoajarticles https://doi.org/10.7705/biomedica.4299 2022-12-31T00:47:09Z Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B. Objective: To evaluate the possible antiparkinsonian effects of the coumarin analogue FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) in mouse models, as well as its inhibitory activity towards monoamine oxidases (MAO) and its antioxidant activity. Materials and methods: FCS005 was synthesized and the reversal of hypokinesia was evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its anticataleptic effects were evaluated. Additionally, the monoamine oxidase inhibitory activity and antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively. Results: FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and levodopa models. This furocoumarin also presented anti-cataleptic effects at the same dose. Besides, it showed selective inhibitory activity towards the MAO-B isoform and antioxidant activity. Conclusion: These results attribute interesting properties to the compound FCS005. It is important to continue research on this molecule considering that it could be a potential antiparkinsonian agent. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Biomédica 39 3 491 501
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
Spanish
topic Parkinson’s disease
monoamine oxidase
coumarins
models
animal
reserpine
levodopa
haloperidol
antioxidants
Medicine
R
Arctic medicine. Tropical medicine
RC955-962
spellingShingle Parkinson’s disease
monoamine oxidase
coumarins
models
animal
reserpine
levodopa
haloperidol
antioxidants
Medicine
R
Arctic medicine. Tropical medicine
RC955-962
María del Pilar Olaya
Nadezdha Esperanza Vergel
José Luis López
María Dolores Viña
Mario Francisco Guerrero
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
topic_facet Parkinson’s disease
monoamine oxidase
coumarins
models
animal
reserpine
levodopa
haloperidol
antioxidants
Medicine
R
Arctic medicine. Tropical medicine
RC955-962
description Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B. Objective: To evaluate the possible antiparkinsonian effects of the coumarin analogue FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) in mouse models, as well as its inhibitory activity towards monoamine oxidases (MAO) and its antioxidant activity. Materials and methods: FCS005 was synthesized and the reversal of hypokinesia was evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its anticataleptic effects were evaluated. Additionally, the monoamine oxidase inhibitory activity and antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively. Results: FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and levodopa models. This furocoumarin also presented anti-cataleptic effects at the same dose. Besides, it showed selective inhibitory activity towards the MAO-B isoform and antioxidant activity. Conclusion: These results attribute interesting properties to the compound FCS005. It is important to continue research on this molecule considering that it could be a potential antiparkinsonian agent.
format Article in Journal/Newspaper
author María del Pilar Olaya
Nadezdha Esperanza Vergel
José Luis López
María Dolores Viña
Mario Francisco Guerrero
author_facet María del Pilar Olaya
Nadezdha Esperanza Vergel
José Luis López
María Dolores Viña
Mario Francisco Guerrero
author_sort María del Pilar Olaya
title Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
title_short Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
title_full Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
title_fullStr Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
title_full_unstemmed Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
title_sort coumarin analogue 3-methyl-7h-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
publisher Instituto Nacional de Salud
publishDate 2019
url https://doi.org/10.7705/biomedica.4299
https://doaj.org/article/0bef9087aca8453f9c128e138c34846b
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source Biomédica: revista del Instituto Nacional de Salud, Vol 39, Iss 3, Pp 491-501 (2019)
op_relation https://revistabiomedica.org/index.php/biomedica/article/view/4299
https://doaj.org/toc/0120-4157
0120-4157
doi:10.7705/biomedica.4299
https://doaj.org/article/0bef9087aca8453f9c128e138c34846b
op_doi https://doi.org/10.7705/biomedica.4299
container_title Biomédica
container_volume 39
container_issue 3
container_start_page 491
op_container_end_page 501
_version_ 1766339690945839104